You can multiply it by 100, but it ain’t happening in real world with this management. They will sell large number of C shares at under a dollar and throw the existing retail shareholders under the bus. Not the first time they will do that, but wait and watch. If it was within them they would have already done this massive dilution, but no investor wants to risk such a significant amount without getting solid confirmation on regulatory status.
They are also very good at moving the goal posts. Once MAA is submitted, acceptance of the application will be hyped and once that is done the expectations will be built around MHRA approvals….when nothing happens at that point in the second half of next year then the talks will move to FDA while the share price continues to languish under a dollar. We have a rich history of that with this management!